Scholarlink

Introduction <p>This study describes the epidemiological and drug resistance characteristics of <i>Bordetella</i> pertussis (<i>B. pertussis</i>) isolated from chronic/protracted cough patients in Beijing, China.</p> Methods <p>A total of 160 patients with chronic/protracted cough from two hospitals in Beijing from 2022 to 2023 were enrolled in this study. Culture, real-time PCR assays and anti-pertussis toxin IgG antibody (PT-IgG) determination were used to confirm the pertussis diagnosis. Forty samples collected between September and November 2023 were screened for 200 respiratory pathogens via targeted next-generation sequencing (tNGS). Antimicrobial susceptibility testing for <i>B. pertussis</i> strains was performed via the E test.</p> Results <p>In this study, 98 patients were diagnosed with laboratory-confirmed cases of pertussis, for a diagnosis rate of 61.25% (98/160). The number of enrolled cases and laboratory-confirmed cases of pertussis increased from July to December 2023, and the highest number of enrolled and laboratory-confirmed cases of pertussis were observed in the age group of 6–12 years. In total, 49 <i>B. pertussis</i> isolates were derived from chronic/protracted cough patients, and the MICs of clindamycin (&gt; 256&#xa0;µg/mL), erythromycin (&gt; 256&#xa0;µg/mL), azithromycin (&gt; 256&#xa0;µg/mL) and sulfamethoxazole (&gt; 1024&#xa0;µg/mL) were greater than the maximum tested concentrations. <i>B. pertussis</i>-related gene fragments were detected in 17 samples via tNGS, with a detection rate of 42.50% (17/40).</p> Conclusions <p>Patients with chronic/protracted cough in this region have a high rate of laboratory-confirmed pertussis. It is important to collect multiple samples during the course of pertussis, as well as to apply various pathogenetic and serologic methods to improve laboratory-based pertussis surveillance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of pertussis surveillance data (2022–2023) in a district of Beijing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Yuanyuan Wang,
  • Hairui Wang,
  • Ying Li,
  • Aixia Yan,
  • Ying Kang,
  • Lijun Liu,
  • Lei Xiao,
  • Shoufei Li,
  • Fengshuang wang,
  • Shengtian Liu,
  • Tao Peng,
  • Maojun Zhang,
  • Zhujun Shao

摘要

Introduction

This study describes the epidemiological and drug resistance characteristics of Bordetella pertussis (B. pertussis) isolated from chronic/protracted cough patients in Beijing, China.

Methods

A total of 160 patients with chronic/protracted cough from two hospitals in Beijing from 2022 to 2023 were enrolled in this study. Culture, real-time PCR assays and anti-pertussis toxin IgG antibody (PT-IgG) determination were used to confirm the pertussis diagnosis. Forty samples collected between September and November 2023 were screened for 200 respiratory pathogens via targeted next-generation sequencing (tNGS). Antimicrobial susceptibility testing for B. pertussis strains was performed via the E test.

Results

In this study, 98 patients were diagnosed with laboratory-confirmed cases of pertussis, for a diagnosis rate of 61.25% (98/160). The number of enrolled cases and laboratory-confirmed cases of pertussis increased from July to December 2023, and the highest number of enrolled and laboratory-confirmed cases of pertussis were observed in the age group of 6–12 years. In total, 49 B. pertussis isolates were derived from chronic/protracted cough patients, and the MICs of clindamycin (> 256 µg/mL), erythromycin (> 256 µg/mL), azithromycin (> 256 µg/mL) and sulfamethoxazole (> 1024 µg/mL) were greater than the maximum tested concentrations. B. pertussis-related gene fragments were detected in 17 samples via tNGS, with a detection rate of 42.50% (17/40).

Conclusions

Patients with chronic/protracted cough in this region have a high rate of laboratory-confirmed pertussis. It is important to collect multiple samples during the course of pertussis, as well as to apply various pathogenetic and serologic methods to improve laboratory-based pertussis surveillance.